Live search
TopFind is fetching the latest matches for your search.
We reviewed 58 live results for besremi ropeginterferon alfa 2b and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Pharmaceuticals and Haematology.
Source: PharmaEssentia Singapore Pte. Ltd.
Description
Besremi is a prescription-only biological therapeutic specifically approved for the treatment of Polycythemia Vera (PV) in adults. This long-acting monopegylated interferon is delivered as a 500 micrograms/mL solution for injection in a prefilled syringe, designed for convenient administration and prolonged therapeutic effect in managing myeloproliferative neoplasms (MPN). It was officially launched in Singapore in September 2024 following approval by the Health Sciences Authority (HSA).
Best for
Patients with Polycythemia Vera, Long Acting interferon therapy, Specialized haematology care and Prescription biological treatments
Rating
Source: PharmaEssentia
Description
Besremi (ropeginterferon alfa-2b) is a solution for injection provided in a 500 mcg/mL pre-filled syringe. It is a monopegylated interferon specifically indicated for the treatment of adults with Polycythemia Vera (PV). It was recently registered by the Health Sciences Authority (HSA) in May 2024 and launched in Singapore in September 2024 as a new long-acting interferon option.
Best for
Polycythemia Vera patients, Long Acting interferon therapy, Newly registered HSA treatments and Hematology patients
Rating
Source: Centre for Clinical Haematology (CFCH)
Description
Professional medical service involving the specialist consultation, prescription, and clinical administration of Besremi (ropeginterferon alfa-2b) for the treatment of Polycythemia Vera. The service includes patient monitoring and expert management of Myeloproliferative Neoplasms (MPNs) in a clinical setting.
Best for
MPN patient management, Supervised biological injections, Specialist haematology advice and Private oncology care
Rating
| Compare | Besremi (ropeginterferon alfa-2b) | Besremi | Besremi Clinical Consultation and Administration |
|---|---|---|---|
| Source | PharmaEssentia Singapore Pte. Ltd. | PharmaEssentia | Centre for Clinical Haematology (CFCH) |
| Description | Besremi is a prescription-only biological therapeutic specifically approved for the treatment of Polycythemia Vera (PV) in adults. This long-acting monopegylated interferon is delivered as a 500 micrograms/mL solution for injection in a prefilled syringe, designed for convenient administration and prolonged therapeutic effect in managing myeloproliferative neoplasms (MPN). It was officially launched in Singapore in September 2024 following approval by the Health Sciences Authority (HSA). | Besremi (ropeginterferon alfa-2b) is a solution for injection provided in a 500 mcg/mL pre-filled syringe. It is a monopegylated interferon specifically indicated for the treatment of adults with Polycythemia Vera (PV). It was recently registered by the Health Sciences Authority (HSA) in May 2024 and launched in Singapore in September 2024 as a new long-acting interferon option. | Professional medical service involving the specialist consultation, prescription, and clinical administration of Besremi (ropeginterferon alfa-2b) for the treatment of Polycythemia Vera. The service includes patient monitoring and expert management of Myeloproliferative Neoplasms (MPNs) in a clinical setting. |
| Best for | Patients with Polycythemia Vera, Long Acting interferon therapy, Specialized haematology care and Prescription biological treatments | Polycythemia Vera patients, Long Acting interferon therapy, Newly registered HSA treatments and Hematology patients | MPN patient management, Supervised biological injections, Specialist haematology advice and Private oncology care |
| Action | |||
| Rating |
If you want the most balanced option to start with, I recommend:
"Besremi (ropeginterferon alfa-2b) from PharmaEssentia Singapore Pte. Ltd.."
I picked this because As the official local subsidiary of the manufacturer, this entity provides the primary source-backed pharmaceutical supply and regulatory oversight for Besremi in Singapore.